Edesa Biotech, Inc. (EDSA )

Currency in USD Disclaimer
$2.38 +$0.02 (0.85%)
Closed 03/13/2025
$2.34
$2.49
$1.55
$5.59

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol EDSA
  • Company Edesa Biotech, Inc.
  • Price $2.38
  • Changes Percentage 0.85
  • Change 0.02
  • Day Low $2.34
  • Day High $2.49
  • Year High $5.59
  • Year Low $1.55
  • Market Cap $16,642,459
  • Price Avg 50 EMA (D) $2.06
  • Price Avg 200 EMA (D) $3.37
  • Exchange NASDAQ
  • Volume 10,968
  • Average Volume 2,020,838
  • Open $2.49
  • Previous Close $2.36
  • EPS -1.87
  • PE -1.27
  • Earnings Announcement 2025-05-08 20:00:00
  • Shares Outstanding $6,992,630

Company brief: EDESA BIOTECH, INC. (EDSA )

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

EDSA Corporation News

Income Statement